Survodutide
SYNCHRONIZE™-2
Boehringer Ingelheim · Phase 3 · Completed · Enrollment 755
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Survodutide 3.6 mg | n/r | n/r | n/r | n/r |
| Survodutide 6.0 mg | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- Survodutide 3.6 mg: endpoint not reported
- Survodutide 6.0 mg: endpoint not reported
- Placebo: endpoint not reported